Group 1 - The core issue raised by investors concerns the adjustment of the value-added tax (VAT) rate from 3% to 13% and its potential impact on the company's tax costs and profits [1] - The company clarified that rare disease drugs within blood products, such as PCC and factors VIII and IX, will continue to be subject to the 3% simplified tax rate, while other blood product businesses will no longer qualify for this rate [1] - The company emphasized its commitment to improving supply chain management and operational practices in response to tax policy changes, aiming to create value for the company and its shareholders [1]